Utility and limitations of 3,3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis

European Heart Journal Cardiovascular Imaging

Volumn 15, Issue 11, 2014, Pages 1289-1298

  Hutt, David F ^a   Quigley, Anne Marie ^b   Page, Joanne ^b   Hall, Margaret L ^b   Burniston, Maria ^b   Gopaul, Dorothea ^a   Lane, Thirusha ^a   Whelan, Carol J ^a   Lachmann, Helen J ^a   Gillmore, Julian D ^a   Hawkins, Philip N ^a   Wechalekar, Ashutosh D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

99mTc DPD scintigraphy; ATTR; Cardiac amyloid; Soft tissue; Transthyretin

Indexed keywords

3,3 DIPHOSPHONO 1,2 PROPANODICARBOXYLIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BISPHOSPHONIC ACID DERIVATIVE; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,1-DIPHOSPHONOPROPANE-2,3-DICARBOXYLIC ACID;

ADULT; AGED; ARTICLE; BONE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FAMILIAL AMYLOIDOSIS; FEMALE; HEART AMYLOIDOSIS; HEART SCINTISCANNING; HUMAN; HUMAN TISSUE; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE; WILD TYPE; AMYLOIDOSIS; BIOPSY; DIAGNOSTIC USE; GENETICS; HEART DISEASE; MIDDLE AGED; SCINTISCANNING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BIOPSY; DIPHOSPHONATES; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84925458040     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jeu107     Document Type: Article

References (20)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349: 583-96.
2. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart 2012;98:1546-54.
3. Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607-14.
4. Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol 2003;17: 909-27.
5. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008;40:232-9.
6. DubreySW, Cha K, Anderson J, Chamarthi B, Reisinger J, SkinnerMet al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med 1998;91:141-57.
7. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch. Intern. Med. 2005;165:1425-9.
8. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047-60.
9. Sachchithanantham S,Wechalekar AD. Imaging in systemic amyloidosis. Br Med Bull 2013;107:41-56.
10. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2- propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
11. Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of Tc-99m-DPD scintigraphy in cardiac amyloidosis. J. Am. Coll. Cardiol. 2008;51:1509-10.
12. Rapezzi C, QuartaCC, Guidalotti PL, Longhi S, Pettinato C, LeoneOet al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8.
13. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99 m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.
14. Falk RH, LeeVW, Rubinow A, Skinner M, CohenAS. Cardiac technetium-99 mpyrophosphate scintigraphy in familial amyloidosis. Am J Cardiol 1984;54:1150-1.
15. Ptacin MJ. Myocardial uptake of technetium-99 m pyrophosphate in systemic amyloidosis. Am J Cardiol 1984;54:938-9.
16. Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, SteinerD et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29:376-9.
17. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54: 213-20.
18. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serumamyloid P component.NEngl JMed1990;323:508-13.
19. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355-64.
20. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-28